CL2020001123A1 - Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren. - Google Patents

Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren.

Info

Publication number
CL2020001123A1
CL2020001123A1 CL2020001123A CL2020001123A CL2020001123A1 CL 2020001123 A1 CL2020001123 A1 CL 2020001123A1 CL 2020001123 A CL2020001123 A CL 2020001123A CL 2020001123 A CL2020001123 A CL 2020001123A CL 2020001123 A1 CL2020001123 A1 CL 2020001123A1
Authority
CL
Chile
Prior art keywords
antibodies
syndrome
treatment
sjögren
therapies
Prior art date
Application number
CL2020001123A
Other languages
English (en)
Inventor
Pascal Espie
Peter Gergely
James Rush
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2020001123A1 publication Critical patent/CL2020001123A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA DIVULGACIÓN SE REFIERE A MÉTODOS, REGÍMENES DE TRATAMIENTO, USOS, EQUIPOS Y TERAPIAS PARA TRATAR EL SÍNDROME DE SJÖGREN, MEDIANTE EL EMPLEO DE ANTICUERPOS ANTI–CD40.
CL2020001123A 2017-11-03 2020-04-28 Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren. CL2020001123A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762581212P 2017-11-03 2017-11-03
US201862644939P 2018-03-19 2018-03-19

Publications (1)

Publication Number Publication Date
CL2020001123A1 true CL2020001123A1 (es) 2020-10-30

Family

ID=64572395

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001123A CL2020001123A1 (es) 2017-11-03 2020-04-28 Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren.

Country Status (13)

Country Link
US (2) US12065499B2 (es)
EP (1) EP3704158A1 (es)
JP (2) JP2021501748A (es)
KR (1) KR20200074993A (es)
CN (1) CN111263771A (es)
AU (2) AU2018361743A1 (es)
BR (1) BR112020008379A2 (es)
CA (1) CA3076872A1 (es)
CL (1) CL2020001123A1 (es)
IL (1) IL273848A (es)
MX (1) MX2020004411A (es)
TW (1) TW201922783A (es)
WO (1) WO2019087094A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018361743A1 (en) 2017-11-03 2020-04-09 Novartis Ag Anti-CD40 antibodies for use in treatment of Sjogren's syndrome
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
MX2021014161A (es) 2019-05-23 2022-01-04 Novartis Ag Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
CN116234909A (zh) * 2020-08-21 2023-06-06 上海药明生物技术有限公司 Cd40激动剂抗体和使用方法
IL300765A (en) * 2020-08-25 2023-04-01 Bristol Myers Squibb Co A method for treating an autoimmune disease with antagonistic CD40 monoclonal antibodies
AU2022358509A1 (en) * 2021-09-28 2024-03-28 Viela Bio, Inc. Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome
AU2024243083A1 (en) * 2023-04-03 2025-11-20 Sialbio Co., Ltd. Pharmaceutical composition for preventing or treating sjogren's syndrome, containing recombinant anti-semaphorin 4d antibody as active ingredient
WO2025210517A1 (en) * 2024-04-02 2025-10-09 Kiniksa Pharmaceuticals, Gmbh Humanized anti-cd40 antibodies for treating sjögren's disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
BRPI0417266B8 (pt) 2003-12-25 2021-05-25 Kyowa Hakko Kirin Co Ltd anticorpo monoclonal, seu uso e composição farmacêutica
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
BR112012024713B1 (pt) 2010-03-31 2021-02-17 Boehringer Ingelheim International Gmbh anticorpo humanizado, seus usos e composição farmacêutica que o compreende
EP2625203A1 (en) * 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
CR20180177A (es) * 2015-09-30 2018-06-22 Janssen Biotech Inc Anticuerpos agonistas que se unen específicamente a cd40 humana y método de uso
AU2018361743A1 (en) 2017-11-03 2020-04-09 Novartis Ag Anti-CD40 antibodies for use in treatment of Sjogren's syndrome

Also Published As

Publication number Publication date
AU2018361743A1 (en) 2020-04-09
AU2022201425A1 (en) 2022-03-24
RU2020117365A3 (es) 2021-12-24
KR20200074993A (ko) 2020-06-25
TW201922783A (zh) 2019-06-16
JP2021501748A (ja) 2021-01-21
CN111263771A (zh) 2020-06-09
MX2020004411A (es) 2020-08-06
RU2020117365A (ru) 2021-12-03
WO2019087094A1 (en) 2019-05-09
JP2022137233A (ja) 2022-09-21
US20190153111A1 (en) 2019-05-23
US20250206833A1 (en) 2025-06-26
CA3076872A1 (en) 2019-05-09
BR112020008379A2 (pt) 2020-11-03
IL273848A (en) 2020-05-31
US12065499B2 (en) 2024-08-20
JP7357120B2 (ja) 2023-10-05
EP3704158A1 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
CL2020001123A1 (es) Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren.
MX2022015631A (es) Anticuerpos anti-cd40 humanizados y usos de los mismos.
MX2017011834A (es) Macrociclos peptidomimeticos y usos de los mismos.
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
CL2021002889A1 (es) Anticuerpos anti-cd40 para uso en el tratamiento de la t1dm y la insulitis
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
PH12017500825A1 (en) Anti-cldn chimeric antigen receptors and methods of use
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
EA201790737A1 (ru) Комбинированная терапия
JO3553B1 (ar) تعديل المناعة ضد الورم
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MY192999A (en) Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
MX393818B (es) Terapias de combinación para el tratamiento de cáncer.
ECSP17081322A (es) Moduladores alostéricos positivos del receptor muscarínico m2
MX2017005325A (es) Enfoque de inmunoterapias de combinación para el tratamiento del cancer.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
CL2021001829A1 (es) Anticuerpos anti–cd40 para el uso en el tratamiento de hidradenitis supurativa
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
MX383323B (es) Grelina para uso en el tratamiento de lesión del cerebro traumática leve.
MX2017000306A (es) Metodos para tratar hipotension.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
PH12017501930A1 (en) Calicheamicin contructs and methods of use
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions